Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - ivabradine oxalate - film coated tablet - 7.5 milligram - ivabradine

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

teva b.v. - ivabradine adipate - film coated tablet - 5 milligram - other cardiac preparations

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

teva b.v. - ivabradine adipate - film coated tablet - 7.5 milligram - other cardiac preparations

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - ivabradine - film coated tablet - 2.5 milligram - other cardiac preparations

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - ivabradine - film coated tablet - 5 milligram - other cardiac preparations

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - ivabradine - film coated tablet - 7.5 milligram - other cardiac preparations

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

les laboratoires servier - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectorisivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated:in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

"anpharm" przedsiębiorstwo farmaceutyczne s.a. - ivabradine - angina pectoris; heart failure - other cardiac preparations - symptomatic treatment of chronic stable angina pectorisivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated:in adults unable to tolerate or with a contra-indication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal betablocker dose.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

jensonr+ limited - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated: - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. treatment of chronic heart failure ivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.,

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. (miol) - ranolazine - angina pectoris - cardiac therapy - ranexa is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies (such as beta-blockers and / or calcium antagonists).,